SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp decline alongside semiconductor peers, after Intels weak outlook and amid concerns about AI-spending returns and high valuations, has made the companys upcoming earnings and guidance a key test. Traders disagree on whether the drop is sympathy selling and a buying opportunity or a sign that demand expectations and valuations are being reset.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is dominating discussion, with traders focused on whether guidance can clear already-elevated expectations as well as the earnings results themselves. Bulls expect continued AI-driven growth, while bears argue the stocks high valuation leaves little room for disappointment, particularly amid a broader pullback in AI shares.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

S&Ps negative outlook, citing uncertainty around Metas heavy AI infrastructure spending and free cash flow, has intensified concerns about its planned equity issuance and dilution. Bearish traders see spending and weak cash generation weighing on the shares, while bulls point to resilient advertising and potential AI monetization.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell shares have drawn attention after reports of advanced, unconfirmed talks to acquire Lumentum, with investors focused on the potential deals size and the risk of shareholder dilution or added debt. Traders are split between viewing Lumentums optical technology as a strategic fit for AI data centers and seeing the acquisition as too costly, while some are buying the sharp selloff.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

Discussion centers on TRUMPs steep decline and accusations that it is a Trump-linked pump-and-dump, with many holders voicing regret and expecting further losses. Some traders still anticipate another pump or short squeeze, leaving sentiment sharply divided.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has fueled discussion of heavy call buying and a possible short squeeze, with traders speculatingwithout confirmationthat a buyout could be behind the move. Others point to the upcoming Q3 report and continued BRIUMVI growth as the more concrete drivers, while debating whether the rally has already priced in good news.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

XLV is drawing attention for its strong rally and healthcares relative strength as traders describe money rotating toward defensive sectors amid weakness in tech. Many see the breakout and broad sector momentum as bullish, while some caution that the move may be extended and due for a pullback.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Iran-related tensions and threats to oil shipping through the Strait of Hormuz are driving attention to USO, with traders focused on possible supply disruptions and low global inventories. Bulls see continued conflict as supportive of oil, while bears expect diplomacy or a ceasefire to ease the risk premium; uncertainty around negotiations is fueling sharp debate.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention ahead of its Q3 earnings report, with investors looking for evidence that Auvelity sales are accelerating, particularly after its launch for Alzheimers-related agitation. The sharp share-price decline has fueled debate over whether prescription trends signal a slower-than-expected launch or undercount demand from samples and long-term-care settings, while investors also want clarity on spending and the path to profitability.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples upcoming quarterly report is the dominant focus, with traders debating whether results and guidance can justify its rich valuation amid memory-cost and margin concerns. Some expect a pullback after the stocks strong run, while others see its restrained AI spending and relative resilience amid tech-sector pressure as defensive strengths.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.03, moving 4.95% from the previous trading session.

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.8, signifying a +2.7% move from its prior day's close.

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion Pharmaceuticals (RXRX) reached $3.66 at the closing of the latest trading day, reflecting a +1.39% change compared to its last close.

RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today? 

Equity

Sanofi selected its first drug development candidate under its collaboration with Recursion.

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.01, moving 8.03% from the previous trading session.

Tempus AI Expands Strategic Collaborations to Drive Future Growth

TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>Recursion could receive over $300 million in additional milestone payments from the program.</li><li>Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.</li><li>Recursion priced a $200 million underwritten offering at $3.25 per share.</li></ul>Shares of Recursion Pharmaceuticals (RXRX) surged more than 16% on Thursday after French drugmaker Sanofi (SNY) selected an experimental treatment for inflammatory diseases developed through their multi-program research collaboration.The update comes alongside a $200 million stock offering that Recursion expects will fund operations into 2029.If the current levels hold, <a class="mention" data-mention="$RXRX" data-symbol-id="RXRX" href="https://stocktwits.com/symbol/RXRX" target="_blank">RXRX stock</a> would record its biggest single-day gains in almost a year.&nbsp;<h2 class="st-heading-2">Sanofi Picks First Drug Candidate Under Partnership</h2>Sanofi’s selection triggered a $10 million milestone payment for Recursion. The experimental oral drug targets two biological mechanisms involved in inflammatory diseases. It is designed to target two biological factors involved in inflammatory diseases.Recursion used its AI-enabled drug design platform and small-molecule chemistry capabilities along with Sanofi’s expertise in drug discovery and immunology to develop the drug.Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.Recursion has now received $144 million in upfront and milestone payments under the partnership. It could earn more than $300 million in additional payments from this program, alongside royalties if the drug is commercially approved.Sanofi and Exscientia signed a drug development partnership in January 2022. Exscientia was subsequently merged with Recursion two years later.The agreement covers up to 15 potential therapies targeting cancer and immune-related diseases, with Recursion eligible for about $5.2 billion in milestone payments if all programs meet their targets.<h2 class="st-heading-2">Recursion’s $200M Fundraising</h2>Recursion also priced a public offering of 61.5 million shares at $3.25 each, aiming to raise about $200 million before expenses. This was a 13% discount to the stock’s closing price on Wednesday.Investors participating in the offering include ARK Invest, Janus Henderson Investors, Invus and Driehaus Capital Management.Recursion had around $561 million in preliminary cash, cash equivalents and restricted cash at the end of September. September-end. Its new equity offering is expected to extend its projected cash runway into 2029.<h2 class="st-heading-2">Retail’s Take On RXRX</h2>Retail sentiment on Stocktwits surrounding RXRX remained ‘bearish’ over the past 24 hours despite the rally.The stock is up about 2% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/spacex-united-airlines-after-aal-rollout-starlink/cZxWys7RBrb">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/fmc-stock-crashes-on-massive-earnings-downgrade-citi-expects-modest-negative-reaction-for-peer-corteva/cZxhGzwRBr3">FMC Stock Crashes 33% On Massive Earnings Downgrade – Citi expects ‘Modest Negative Reaction’ For Peer Corteva</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Recursion is an American biotechnology company that combines machine learning, automation, and experimental biology. (Photo illustration by Cheng Xin/Getty Images)

Recursion Pharmaceuticals Inc

Sanofi-Aventis

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.03
Prev Close	$4.24
Open	$4.05
Dividend Yield	0.00%
50-Day Moving Average	$3.74
Beta	2.88
Avg. Volume	20.48M
PE Ratio	-3.89

52-Week High	$5.76
52-Week Low	$2.77
Market Capitalization	$2.41B
EPS (Annual)	-$1.44
Price to Book	2.35
Revenue Per Employee	$124,468.33

Feed

News

Sentiment

Earnings

Fundamentals

Info

RXRX Fundamentals